The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Patient Advocacy – Poster Session (P808-P815) - Takeaways - MDSpire

The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Patient Advocacy – Poster Session (P808-P815)

  • October 8, 2024

  • 0 min

Share

  • 1

    The Lymphoma Coalition's 2022 Global Patient Survey included 5280 patients, revealing significant global disparities in aHSCT utilization.

  • 2

    Younger patients were more likely to receive aHSCT, while biological sex did not significantly influence treatment utilization.

  • 3

    The highest aHSCT utilization rates were observed in the Middle East and Africa, contrasting with North America's low rate of 4%.

  • 4

    Over 70% of patients receiving aHSCT also underwent additional treatments, with many experiencing at least one relapse.

  • 5

    The study emphasizes the need for diverse therapeutic options and aims to inform global trends in lymphoma treatment.

Original Source(s)

The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Patient Advocacy – Poster Session (P808-P815)

  • October 8, 2024

Related Content

Blocking CD30 on CD19 CAR T cells augments their functional capacities against B-cell leukemia/lymphoma

The First NCI-Designated Comprehensive Cancer Center Using 3D Genomics Testing to Diagnose Lymphoma and Sarcoma—a True Game Changer

Diagnosing lymphoma and sarcoma can be extraordinarily complex, with more than 70 recognized subtypes of lymphoma and more than 100 distinct types of sarcoma. Many subtypes share similar features yet behave in dramatically different ways in standard testing, leaving oncologists with diagnostic quandaries and delays to treatment.

  • by

  • February 24, 2026

  • 4 min
Fertility preservation and subsequent reproductive outcomes in female pediatric patients with hematologic malignancies